Reports Net Loss of *$9.9 Million or $0.23 per Diluted Share, and Adjusted EBITDA of ($7.3) Million *Impacted by the timing of separated RIN sales of $19.5 million not realized until July CLAYTON, Mo., Aug. 09, 2023 (GLOBE NEWSWIRE) -- FutureFuel Corp. ( …
ORLANDO, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenues of $27,877,000 for the quarter ended June 30, 2023 compared to $29,647,000 for the quarter ended June 30 …
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data …
Revenue grew 18% year-over-year to a record $35.9 million; telehealth net revenues increased 11% versus the first quarter of 2023. Achieved positive free cash flow, ahead of guidance. Adjusted EBITDA increased to $1.7 million in the second quarter 2023 …
Herpesvirus candidate ABI-5366 anticipated to enter clinic in first half of 2024 New data for several pipeline programs presented at IHW and EASL 2023 Additional development candidate nomination expected in 2023 SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 ( …
FREMONT, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- ACM Research, Inc. (ACM) (NASDAQ: ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced wafer-level packaging applications, today announced its participation in the …
SUNNYVALE, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of …
- Key Catalysts ahead with Multiple Value Generating Readouts- - Expects to Release Phase 1/2 Data with Oral Fadraciclib - - Signals of Single-agent Efficacy with Oral Plogosertib - - Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY …
THORNTON, Colo., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Sonder Holdings Inc. (NASDAQ: SOND), a leading next-generation hospitality company that is redefining the guest experience through technology and design, today announced second quarter 2023 financial …
FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality non-inferiority margin of 10% FDA provided alternative trial …
– Dutch Ministry of Health Approves VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce the Risk of Cardiovascular Events in Patients with Established Cardiovascular Disease – – Italy’s AIFA Pricing & Reimbursement Committee (CPR) Issues …
SHOEMAKERSVILLE, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled …
AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that …
RENO, Nev., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals" or the "Company”), a pioneer in sustainable lithium battery recycling, today announced financial results and provided a business update for the second …
Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401 Anticipated in Second Half 2023 Second Quarter Cash and …
BROOMFIELD, Colo., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for its second quarter ended July 4, 2023. Key highlights for the second quarter of 2023 versus the second quarter of 2022 include: …
TORONTO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …
ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next- …
Presented positive interim data from intravitreal 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD) Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM …
WALTHAM, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D …
01 days 20:01:01
